Abstract
This study aimed to investigate the effects of SOST and the Wnt/β-catenin signaling pathway on the proliferation, migration, invasion, and apoptosis of human retinoblastoma cells. Fifty-five retinoblastoma and 21 normal retinal tissue samples were collected as the case group and control group, respectively. HXO-RB44 and SO-RB50 cells were selected and assigned into blank, negative control (NC), siRNA 1, siRNA 2, siRNA 3, IWR-1-endo 1, IWR-1-endo 2 and IWR-1-endo 3 groups. Quantitative real-time polymerase chain reaction (qRT-PCR) was applied to detect the expression of SOST, Wnt-1, and β-catenin in the collected tissue samples. MTT assay, flow cytometry, transwell assay and the starch test were employed to determine the cell proliferation, cell cycle, apoptosis, invasion and migration after transfection. The qRT-PCR and western blotting were also used to detect the mRNA and protein expressions of SOST, Wnt-1, β-catenin, C-myc, Cyclin D1, MMP-2 and MMP-9. The tumor formation in nude mice was conducted to evaluate the effects of SOST on the growth of a transplanted tumor. Compared with normal retinal tissues, the retinoblastoma tissues exhibited a downregulation of SOST but an upregulation of Wnt-1 and β-catenin. The proliferation, invasion and migration of HXO-RB44 and SO-RB50 cells in the SOST-siRNA group were significantly higher than the cells in the blank and NC groups. The expressions of Wnt-1, β-catenin, C-myc, Cyclin D1, MMP-2 and MMP-9 in the three SOST-siRNA groups were elevated, but the SOST decreased when compared with the blank and NC groups. SOST silencing promoted the growth of transplanted tumors in nude mice. These findings indicate that SOST silencing promotes the proliferation, invasion and migration, and decreases the apoptosis of human retinoblastoma cells by activating the Wnt/β-catenin signaling pathway.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Dean M, Bendfeldt G, Lou H, Giron V, Garrido C, Valverde P et al. Increased incidence and disparity of diagnosis of retinoblastoma patients in Guatemala. Cancer Lett 2014; 351: p 59–63.
Zhang Y, Xue C, Cui H, Huang Z . High expression of TAZ indicates a poor prognosis in retinoblastoma. Diagn Pathol 2015; 10: 187.
Dimaras H, Kimani K, Dimba EA, Gronsdahl P, White A, Chan HS et al. Retinoblastoma. Lancet 2012; 379: 1436–1446.
Wang XQ, Wang YC, Guo YT, Tang X . Effect of piperlongumine on drug resistance reversal in human retinoblastoma HXO-RB44/VCR and SO-Rb50/CBP cell lines. Int J Clin Exp Pathol 2015; 8: 2525–2534.
Shields CL, Lally SE, Leahey AM, Jabbour PM, Caywood EH, Schwendeman R et al. Targeted retinoblastoma management: when to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Curr Opin Ophthalmol 2014; 25: 374–385.
Gao Y, Lu X . Decreased expression of MEG3 contributes to retinoblastoma progression and affects retinoblastoma cell growth by regulating the activity of Wnt/beta-catenin pathway. Tumour Biol 2016; 37: 1461–1469.
Semenov M, Tamai K, He X . SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 2005; 280: 26770–26775.
Piec I, Washbourne C, Tang J, Fisher E, Greeves J, Jackson S et al. How accurate is your sclerostin measurement? comparison between three commercially available sclerostin ELISA Kits. Calcif Tissue Int 2016; 98: p 546–555.
Bao X, Liu Y, Han G, Zuo Z, Hu M . The effect on proliferation and differentiation of cementoblast by using sclerostin as inhibitor. Int J Mol Sci 2013; 14: 21140–21152.
Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001; 68: 577–589.
Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001; 10: 537–543.
Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005; 280: 19883–19887.
Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW et al. Small molecule-mediated disruption of wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009; 5: 100–107.
Wang Y, Sang A, Zhu M, Zhang G, Guan H, Ji M et al. Tissue factor induces vegf expression via activation of the wnt/beta-catenin signaling pathway in arpe-19 cells. Mol Vis 2016; 22: 886–897.
Kivela T . The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol 2009; 93: 1129–1131.
Schundeln MM, Hauffa PK, Bauer JJ, Temming P, Sauerwein W, Biewald E et al. Pediatric survivors of retinoblastoma are at risk for altered bone metabolism after chemotherapy treatment early in life. Pediatr Hematol Oncol 2015; 32: 455–466.
Khosravi A, Shahrabi S, Shahjahani M, Saki. N . The bone marrow metastasis niche in retinoblastoma. Cell Oncol 2015; 38: 253–263.
Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001; 107: 513–523.
Balemans W, Piters E, Cleiren E, Ai M, Van Wesenbeeck L, Warman ML et al. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations. Calcif Tissue Int 2008; 82: 445–453.
Parisi T, Bronson RT, Lees JA . Inactivation of the retinoblastoma gene yields a mouse model of malignant colorectal cancer. Oncogene 2015; 34: 5890–5899.
Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014; 505: 495–501.
Basolo F, Caligo MA, Pinchera A, Fedeli F, Baldanzi A, Miccoli P et al. Cyclin D1 overexpression in thyroid carcinomas: relation with clinico-pathological parameters, retinoblastoma gene product, and Ki67 labeling index. Thyroid 2000; 10: 741–746.
Waas ET, Wobbes T, Lomme RM, DeGroot J, Ruers T, Hendriks T . Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis. Br J Surg 2003; 90: 1556–1564.
Zhang L, Shi J, Feng J, Klocker H, Lee C, Zhang J . Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer Prostatic Dis 2004; 7: 327–332.
Long H, Zhou B, Jiang FG . Expression of MMP-2 and MMP-9 in retinoblastoma and their significance. Int J Ophthalmol 2011; 4: 489–491.
Ghassemi F, Chams H, Sabour S, Karkhaneh R, Farzbod F, Khodaparast M et al. Characteristics of germline and non-germline retinoblastomas. J Ophthalmic Vis Res 2014; 9: 188–194.
Acknowledgements
We give our sincere appreciation to the reviewers for their helpful comments on this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Wu, T., Wang, LN., Tang, DR. et al. SOST silencing promotes proliferation and invasion and reduces apoptosis of retinoblastoma cells by activating Wnt/β-catenin signaling pathway. Gene Ther 24, 399–407 (2017). https://doi.org/10.1038/gt.2017.31
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2017.31
This article is cited by
-
Retinoblastoma: present scenario and future challenges
Cell Communication and Signaling (2023)
-
β-asarone attenuates the proliferation, migration and enhances apoptosis of retinoblastoma through Wnt/β-catenin signaling pathway
International Ophthalmology (2022)
-
LncRNA MBLN1-AS1 inhibits the progression of retinoblastoma through targeting miR-338-5p-Wnt/β-catenin signaling pathway
Inflammation Research (2021)